Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Tropical Diseases: Treatment, Prevention, and Market Opportunities 11/21/2008 \| published by: Decision Resources ... are urgently needed. Perceiving a risk to ROI, pharma companies have often shied away from research in these areas, leaving discovery to charitable organizations. However, the expected migration of these diseases into new geographic regions, ... \| more...	$4,600.00
Value-Added Pharma: How to Accomplish the Impossible 11/20/2008 \| published by: Decision Resources ... wider use of generics-all of which translates into more value at reasonable cost (the value-added proposition). But how does the industry transform itself from where it is now to where it needs to be-how does ... \| more...	$1,125.00
Pharma's Changing Business Strategies: Five Deadly Pharma Sins 10/30/2008 \| published by: Decision Resources ... going to be like the past and that something needs to be done to fundamentally change pharma's business strategies-and fast. The case studies in this report describe management-driven changes currently under way in three leading ... \| more...	$1,668.75
Effective Drug Life Cycle Management: The Crucial Interaction Between Brand Life Span and Market Life Cycle 9/30/2008 \| published by: Decision Resources ... of the brand life span relate to the four stages of the market life cycle. The challenges increase as markets approach the mature and declining stages and generics competition looms. Follow-on products can offer a ... \| more...	$1,125.00
Pharma and the Feds: Key Government Activities and How They Affect the Biopharmaceutical Industry 9/30/2008 \| published by: Decision Resources ... on healthcare; the United States ranks 37th in terms of healthcare outcomes. Healthcare is thus in the spotlight among the population, the legislators who represent the population, and candidates in this year's presidential elections. Certain ... \| more...	$4,600.00
Women's Health Series: How Have New Oral Contraceptives Changed the Market? 9/29/2008 \| published by: Decision Resources ... their primary indication (preventing pregnancy) and safety. As a result, drug developers have implemented a variety of strategies to differentiate their products from one another, including aggressive and expensive direct-to consumer (DTC) marketing campaigns and ... \| more...	$4,600.00
How to Integrate Personalized Medicine into Business Strategies 9/24/2008 \| published by: Decision Resources ... to integrate a personalized medicine approach into business strategies? We provide perspectives from pharmaceutical, diagnostic, and managed care executives and create a set of recommendations based on what experts advise when contemplating the operational shift ... \| more...	$4,600.00
Women's Health Series: Endometriosis--How Will New Therapies Compare with Current Market Leaders? 9/12/2008 \| published by: Decision Resources ... employ mechanisms of action that have been available for several decades. Furthermore, these treatments have significant drawbacks, most notably the loss of bone density and numerous menopause-like side effects. New agents in development may alleviate ... \| more...	$4,600.00
Key Markets in Medicare Part D 8/28/2008 \| published by: Decision Resources ... metabolic disorders, infectious diseases, immune/infl ammatory disorders, and several other key conditions account for a substantial share of Medicare Part D prescribing. This report, featuring 36 data-based figures and 15 statistical tables, examines health insurance ... \| more...	$4,600.00
Pharmaceutical Pricing and Reimbursement in Spain, 2008 8/28/2008 \| published by: Decision Resources ... are among the lowest in Europe and have been eroded by repeated mandatory price cuts. In addition, the government's strategy of promoting generics, imposing reference prices on off-patent drugs, and limiting price premiums to the ... \| more...	$4,600.00
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances 8/27/2008 \| published by: Decision Resources ... current alliances and licensing practices. Multiple business and technological factors are converging to reshape the complex biotech-pharma industry landscape. Get the Answers You Need to Shape Your Strategy Rising deal values, evolving deal structures, and ... \| more...	$4,600.00
Women's Health Series: Is There Change Ahead for the Female Infertility Market? 8/25/2008 \| published by: Decision Resources ... the treatment of infertility has not changed significantly over the past several decades because drug developers have been put off by the relatively small market, reimbursement concerns, and the efficacy of existing treatment. However, there ... \| more...	$4,600.00
Lessons Learned from the Current Crop of Biotech Startups 8/18/2008 \| published by: Decision Resources ... to support a negative trend. The other side of intense pessimism, however, is that money accumulates on the sidelines where life science investors ultimately become impatient with money market returns and look for places to ... \| more...	$4,600.00
Special Report: Key Pricing and Reimbursement Trends for CNS Drugs 7/30/2008 \| published by: Decision Resources ... pharmaceutical sales. However, pharmaceutical companies are subject to intense pressure from payers to moderate their prices. Additionally, physicians and patients face ever-more-daunting reimbursement barriers. Our analysis of the five-year pricing trend for 40 best-selling CNS ... \| more...	$9,200.00
R&D Update: What's on the Horizon for the Panic Disorder Market? 7/30/2008 \| published by: Decision Resources ... for other anxiety disorders. This dearth opens a clear opportunity for an emerging agent that can offer superior efficacy over the available options. Get the Answers You Need to Shape Your Strategy PD can be ... \| more...	$4,600.00
Key Issues to Consider When Bringing Biologics to Market in Europe and Japan 7/28/2008 \| published by: Decision Resources ... force in Europe and Japan, where they are well represented in companies' product pipelines. Issues that will make or break the successful integration of biologics in European and Japanese biopharmaceutical market include clinical trial design, ... \| more...	$1,125.00
Noninvasive Approaches Offer Substantial Market Potential in Liver Disease Diagnostics 7/17/2008 \| published by: Decision Resources ... perceptions of noninvasive approaches, gathered in a series of interviews with leading hepatologists. We provide a general view of the market potential for noninvasive liver diagnostics and the challenges and opportunities for companies seeking to ... \| more...	$1,125.00
How Have Safety Concerns and New Warnings Affected the Anemia Market? 6/26/2008 \| published by: Decision Resources ... and reimbursement, and significant decline in ESA sales ensued. Can the market survive this crisis and return to prosperity? Get the Answers You Need to Shape Your Strategy Concerns about the safety of ESAs have ... \| more...	$1,125.00
SPECIAL REPORT: 2008 Chartbook of International Pharmaceutical Prices 6/26/2008 \| published by: Decision Resources ... cut prices. To best determine pricing, pharmaceutical companies therefore need to be aware of international price differentials; this report provides comparisons of exmanufacturer drug prices among the countries under study and by select therapeutic area. ... \| more...	$2,250.00
SPECIAL REPORT - Fueling the Drug Discovery Engine: Biotech Investment and Business Trends 6/24/2008 \| published by: Decision Resources ... ensure the long-term prosperity of both? A range of strategic choices offers positive answers. Get the Answers You Need to Shape Your Strategy Promising new therapies and drug discovery approaches are on the horizon, but ... \| more...	$9,200.00
ORPHAN DISEASE SERIES - Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies? 6/20/2008 \| published by: Decision Resources ... the closest we have come to a cure for CF" and will almost certainly bring about a change in the treatment algorithm of the disease. As a result, new market leaders will emerge, and current ... \| more...	$9,200.00
Improving Return on Investment in Pharmaceutical Marketing 6/17/2008 \| published by: Decision Resources ... at almost twice the spend of R&D. How can companies improve their return on investment (ROI)? We propose a three-tiered approach to improve the value of pharmaceutical marketing investments by increasing ROI. Get the Answers ... \| more...	$1,125.00
ORPHAN DISEASE SERIES - Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market? 6/11/2008 \| published by: Decision Resources ... unmet need, especially to address unreliable patient compliance and unacceptable side effects. Additionally, several orphan conditions exist that include glaucoma as a relevant symptom. Focusing on any of these areas could provide an entry for ... \| more...	$9,200.00
Pharmaceutical Pricing and Reimbursement in France, 2008 6/11/2008 \| published by: Decision Resources ... may have to pursue more radical reform in the future, and the pharmaceutical industry will have to adapt to a market that places growing emphasis on the costeffectiveness of treatments. Get the Answers You Need ... \| more...	$1,125.00
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends 6/5/2008 \| published by: Decision Resources ... drug because of their particular metabolic activity. The concept of companion diagnostics as an integral component of personalized medicine-RxDx-is an emerging and critical paradigm for drug development and use. What is driving that paradigm? Get ... \| more...	$1,125.00

< prev 5 6 7 8 9 10 11 12 13 14 next >